T790M (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "T790M" in Chinese language version.

refsWebsite

Global rank Chinese rank

4^th place

5^th place

2^nd place

23^rd place

670^th place

845^th place

1^st place

cam.ac.uk

Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015, 16 (9): e447–59 [2020-11-30]. PMID 26370354. doi:10.1016/S1470-2045(15)00246-6. （原始内容存档于2020-07-17）.
Yun, CH; Mengwasser, KE; Toms, AV; Woo, MS; Greulich, H; Wong, KK; Meyerson, M; Eck, MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.. Proceedings of the National Academy of Sciences of the United States of America. 12 February 2008, 105 (6): 2070–5. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105.
Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015, 11 (22): 3069–81. PMID 26450446. doi:10.2217/fon.15.250.
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006, 12 (1): 6494–501. PMID 17085664. doi:10.1158/1078-0432.CCR-06-1570.
Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Emerging treatment for advanced lung cancer with EGFR mutation. Expert Opin Emerg Drugs. 2015, 20 (4): 1–16. PMID 26153235. doi:10.1517/14728214.2015.1058778.

Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015, 16 (9): e447–59 [2020-11-30]. PMID 26370354. doi:10.1016/S1470-2045(15)00246-6. （原始内容存档于2020-07-17）.
Yun, CH; Mengwasser, KE; Toms, AV; Woo, MS; Greulich, H; Wong, KK; Meyerson, M; Eck, MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.. Proceedings of the National Academy of Sciences of the United States of America. 12 February 2008, 105 (6): 2070–5. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105.
Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015, 11 (22): 3069–81. PMID 26450446. doi:10.2217/fon.15.250.
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006, 12 (1): 6494–501. PMID 17085664. doi:10.1158/1078-0432.CCR-06-1570.
Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Emerging treatment for advanced lung cancer with EGFR mutation. Expert Opin Emerg Drugs. 2015, 20 (4): 1–16. PMID 26153235. doi:10.1517/14728214.2015.1058778.